

Reflex Testing

Corewell Health West

Contents

Anatomical Pathology	2
Chemistry Reflex Testing	5
Coagulation Reflex Testing	6
Cytogenetics Reflex Testing	7
Cytology Reflex Testing	8
Flow Cytometry Reflex Testing	9
Hematology Reflex Testing	10
Hematopathology Reflex Testing	12
Immunochemistry Reflex Testing	13
Microbiology Reflex Testing	15
Molecular Diagnostics Reflex Testing	16
Referrals Reflex Testing	17
Toxicology Reflex Testing	18
Transfusion Medicine/Blood Bank Reflex Testing	19
Urinalysis Reflex Testing	20

*Changes highlighted are approved in current calendar year, highlighting will be removed in subsequent calendar year.

*Under certain circumstances reflex testing may be initiated based on NCCN guidelines, see MEC form (07/13/2020) for more details.

Anatomical Pathology

Anatomic Pathology – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
Brain	
Brain – high grade gliomas	MGMT Methylation Analysis
Breast	
<p>All patients with invasive breast carcinoma meeting the following criteria:</p> <ul style="list-style-type: none"> Age less than 70 years Not pure tubular, mucinous, or colloid carcinoma (grade 1 special subtypes with good prognosis) Tumor is pathologic stage pT1b, T1c, T2, or T3 Tumor is pathologic stage pN0 or N1mi Tumor is ER positive and Her2/neu negative <p>Not post-treatment (y), recurrent tumor (r) or with known distant metastatic tumor (M1)</p>	<p>Send for Oncotype DX testing:</p> <ol style="list-style-type: none"> 1) If multifocal on same side and meet the criteria <ul style="list-style-type: none"> Perform Oncotype on largest primary tumor (if same histology) Perform Oncotype on up to three primary tumors (if different histology), indicate order of testing to Oncotype (as they will stop further testing if high recurrence score is resulted) 2) If bilateral, perform Oncotype on both sides if meet the criteria. <p>If the patient has a different higher risk concurrent breast cancer such pT4, pN1b or more, ER negative, or Her2, do not reflexively test any additional lower risk tumor(s). The higher risk cancer will drive the patient's treatment and prognosis so testing the lower risk one is not done as reflex.</p>
<p>Primary and recurrent/metastatic Invasive Mammary Carcinoma (excisional biopsy / lumpectomy / mastectomy)</p> <p style="text-align: right; margin-right: 20px;">As per NCCN Guidelines 2024</p>	IHC (immunohistochemical) stains for ER, PR, and Her2
<p>Ductal Carcinoma In Situ (DCIS)</p> <p style="text-align: right; margin-right: 20px;">As per NCCN Guidelines 2024</p>	IHC stains for ER and PR
Cardiac	
<p>Tissue submitted for amyloid evaluation from either 1) endomyocardium, 2) synovium, or 3) abdominal fat pad</p> <p style="text-align: right; margin-right: 20px;">MEC Approved March 2025</p>	If positive for amyloid deposition, then tissue will be sent to Mayo Clinical for amyloid subtyping
GI (Gastrointestinal)	
Metastatic gastrointestinal tract adenocarcinomas (gastric, esophageal, small bowel, colon and rectum), including cases highly suspicious for metastatic disease on imaging.	1) Perform Her2/neu (IHC) stain. When metastasis is pathologically confirmed, can use either metastatic site or primary tumor.

Anatomic Pathology – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
As per NCCN guidelines 2022	Equivocal IHC results will reflex to HER2 FISH testing - 2) Perform MMR evaluation (Immunohistochemical protein studies for MSH2, MSH6, MLH1, PMS2), if previously not performed on main tumor. Based on MMR results reflex to additional testing as per current CAP protocol
Metastatic Colorectal Carcinoma	Colon Mutation Analysis Panel (in-house testing)- includes genotyping for KRAS, NRAS, and BRAF mutations
All newly diagnosed gastrointestinal tract (luminal) adenocarcinomas (gastric, esophageal, small bowel, colon and rectum) As per NCCN guidelines 2022	- IHC stains for MSH2, MSH6, MLH1, PMS2 Based on MMR results reflex to additional testing as per current CAP protocol
Gastric (stomach) gastrointestinal stromal tumors (GISTs) with epithelioid morphology As per NCCN guidelines 2022	SHDB immunohistochemical stain
GYN (Gynecological)	
All newly diagnosed or previously untested Adult Granulosa Cell Tumors, Serous Borderline Tumors, and Low-Grade Serous Carcinomas	IHC stains for ER and PR
GYN sentinel lymph nodes which show no evidence of metastasis on initial H&E levels (applies to all GYN sentinel lymph nodes, including, but not limited to, those removed for endometrial, vulvar, and cervical carcinomas).	Cytokeratin AE1/AE3 (to be performed on all blocks of all nodes deemed negative for metastasis following initial review of H&E sections).
All newly diagnosed patients with endometrial cancer, including carcinosarcoma, and including cases of recurrence when no IHC was previously performed. MEC Approved July 2025	<ol style="list-style-type: none"> 1. MSH2, MSH6, MLH1, PMS2 IHC stains Based on MMR results reflex to additional testing as per current CAP protocol 2. Estrogen receptor IHC stain 3. p53 IHC stain 4. POLE molecular testing (in-house) If serous carcinoma or carcinosarcoma: also order HER2 with reflex FISH for equivocal IHC

Anatomic Pathology – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
Head & Neck	
All newly diagnosed or previously untested oropharyngeal squamous cell carcinomas Updated February 2025	p16 immunohistochemistry (surrogate marker for HPV)
Lung	
Stage 4 lung non-small cell carcinoma biopsy or resection (both adenocarcinoma and squamous cell carcinoma) As per NCCN guidelines 2024	PD-L1 (IHC send out test to CH East), and lung molecular panel (in-house test)
Lymph node biopsy/cytology positive for lung non-small cell carcinoma (both adenocarcinoma and squamous cell carcinoma) As per NCCN guidelines 2024	PD-L1 (IHC send out test to CH East), and molecular testing for EGFR and ALK (in-house test)
Resection lung cases of non-small cell carcinoma (both adenocarcinoma and squamous cell carcinoma) which show <ul style="list-style-type: none"> - Tumor size 4 cm or greater - Positive lymph node(s) As per NCCN guidelines 2024	PD-L1 (IHC send out test to CH East), and molecular testing for EGFR and ALK (in-house test)
Melanoma	
Metastatic melanoma Including positive lymph node (and not previously evaluated for BRAF)	BRAF V600E IHC <ul style="list-style-type: none"> - If IHC is negative reflex to molecular <i>BRAF</i> testing
Other	
Her2/neu IHC result is equivocal (score 2+)	Her-2/neu (ERBB2) amplification by FISH

Chemistry Reflex Testing

Chemistry – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
HIV Quick Test (LAB175) performed at Corewell Health Reference Laboratory West	If Reactive, reflex to HIV 1/HIV 2 Ab Ag Diagnostic (Roche) to be performed at Corewell Health Reference Laboratory West.
HIV Quick Test (LAB175) ordered at Corewell Health Reference Laboratory West	The HIV Quick Test is cancelled and reordered as HIV 1/HIV 2 Ab Ag Diagnostic (Roche). <i>(The Abbott HIV Quick Test is not available at the Corewell Health Reference Laboratory West)</i>
HIV 1/HIV 2 Ab Ag Diagnostic (Roche)	If Reactive, reflex to Geenius HIV 1/HIV 2 Antibody Confirmation
Reactive Hepatitis B surface antigen	HbsAg Confirmation test
Prostate Specific Antigen (PSA) Free Level	PSA total on all orders that do not already have a PSA ordered on the same specimen.
Reactive Syphilis IgG Antibody	Reflex to RPR titer at Corewell Health West. If RPR is negative, additional TP-PA testing will be performed by MDHHS
Random urine microalbumin	Urine creatinine
Thyroglobulin	Automatically cancel AntiTgAB request when ordered with srTg
Reactive Hepatitis C Virus Antibody	HCV RNA
Chemistry – Optional	
Initial Test & Result	Optional Follow up Testing
Lipid Panel do LDL Direct if Triglycerides result is > 800 mg/dL Revised 2/2026	LDL Direct
Preg Serum Quant Progesterone if HCG result > 5 mIU/mL	Progesterone level
PSA Sym FPSA if PSA result between 2.5 and 10.0 ng/mL	Free PSA
Thyroid Function Cascade TSH result above 5.0 mcU/mL or TSH result below 0.3 mcU/mL or TSH result below 0.1 mcU/mL and FT4 result below 1.6 ng/dL	FT4 and TPO if TSH is above 5.0 mcU/mL FT4 if TSH is below 0.3 mcU/mL <ul style="list-style-type: none"> • Free T3 if TSH is below 0.1 mcU/mL and FT4 is below 1.6 ng/dL
TSH, Free T4 if indicated TSH result above 5.0 mcU/mL or TSH result below 0.3 mcU/mL	Free T4

Coagulation Reflex Testing

Coagulation – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
aPTT with no endpoint detected or error code on the coagulation analyzer that cannot be resolved.	Unfractionated Heparin
Mixing Studies, aPTT, which does not correct	Lupus Anticoagulant Screen (LA1)
Mixing Studies, aPTT	Heparin Neutralization (to rule out anticoagulant: <ul style="list-style-type: none"> • If aPTT corrects to normal, then a Mixing Study is not indicated. • If aPTT remains elevated, then Unfractionated Heparin Level (anti-Xa assay) is ordered. If Unfractionated Heparin Level is greater than 1.0 U/mL, then aPTT Mixing Study is not indicated.
Mixing Studies, PT, which does not correct	Lupus Anticoagulant Screen (LA1)
Factor activity testing showing non-parallelism inhibitor type pattern on serial dilutions <small>MEC Approved April 2022</small>	Lupus Screen
Factor 8 Activity for patients on emicizumab (Hemlibra) recombinant factor 8 therapy	Chromogenic Factor 8 Activity
Heparin Dependent Antibody (HIT) Positive or Borderline	Serotonin Release Assay (SRA)
Lupus Screen LA1 elevated	Perform LA2 Perform PT and aPTT <ul style="list-style-type: none"> • If PT is elevated ≥ 4 seconds above normal range, perform PT mixing study • If aPTT is elevated ≥ 6 seconds above normal range, perform aPTT mixing study Pathologist interpretation
Platelet Aggregation Studies	Platelet Count and hematocrit
Platelet Function Assay (PFA 100) with Collagen/Epinephrine cartridge results greater than 180 seconds.	Collagen/ADP test
Platelet Function Assay (PFA 100)	Platelet Count and hematocrit
Coagulation Special Tests with abnormal results (Antithrombin III activity, Chromogenic Factor VIII activity, Factor II activity, Factor IX activity, Factor V activity, Factor VII activity, Factor VIII activity, Factor X activity, Factor XI activity, Factor XII activity, Protein C activity, Protein S activity, VerifyNow® Assay for aspirin effect, VerifyNow® P2Y12 assay for antiplatelet effect, von Willebrand factor activity, von Willebrand factor antigen, Mixing studies, APTT, Mixing studies, PT, Platelet aggregation studies) <small>MEC Approved April 2025</small>	Pathologist interpretation

Cytogenetics Reflex Testing

Cytogenetics - Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
Bone Marrow samples with clinical indications for possible need to perform FISH Multiple Myeloma Panel	Sort CD138 to purify (concentrate) sample and hold for possible FISH Multiple Myeloma Panel
Multiple Myeloma Panel: If positive for IGH rearrangement Updated February 2024	Add t(11;14) IGH/CCND1 - If negative for t(11;14) IGH/CCND1 add t(4:14) IGH/FGFR3 and t(14;16) IGH/MAF
DLBCL Panel: If positive for MYC rearrangement ONLY MEC Approved February 2024	Add t(8;14) IGH/MYC/CEP8
DLBCL Panel: If positive for BCL2 with or without BCL6 rearrangement and without MYC rearrangement MEC Approved February 2024	Add t(14;18) IGH/BCL2 dual fusion
Chromosome Analysis Hematologic or Neoplastic Study MEC Approved October 2022	Chromosomal Microarray – Oncology (aCGH-Hematologic)
Constitutional chromosome analysis, mosaic orders WITHOUT indications of Turner Syndrome, short stature, amenorrhea, or any indication associated with an increased risk of mosaicism MEC Approved February 2024	Routine constitutional chromosome analysis will be ordered in place of the mosaic order
Chromosome studies with an indication of Turner Syndrome, short stature, amenorrhea, or any indication with possible mosaicism Previously approved- added 2/2023	PB Mosaic (30 cell analysis)
Additional cell lines in chromosome study Previously approved- added 2/2023	Additional karyotype will be created to represent each addition cell line identified
Abnormal or ambiguous microarray results Previously approved- added 2/2023	May be confirmed by cytogenetic chromosome analysis or fluorescence in situ hybridization (FISH) analysis as appropriate, based on specific abnormality, size and location of region identified
Newborn fluorescence in situ hybridization (FISH) studies Previously approved- added 2/2023	Cytogenetic chromosome analysis as appropriate with abnormal results on interphase FISH testing to fully characterize the abnormality identified
Chromosome Analysis Prenatal and Chromosome Analysis Prenatal Limited orders will now include cryopreservation of prenatal specimens (amniotic fluid and chorionic villi) MEC Approved January 2025	All specimens under these orders will get cryopreserved, excluding those found to have straightforward abnormalities (i.e. whole chromosome copy gain)
B-ALL FISH Panel: If negative for BCR/ABL gene fusion and/or ETV6/RUNX1 gene fusion MEC approved June 2025	Ph+ like testing

Cytology Reflex Testing

Cytology - Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
<p>Pap test and HPV</p> <p style="text-align: right;">Updated April 2025</p>	<p>Reflex Information</p> <p>Is HPV Requested?</p> <p>a. If NO HPV testing is desired, select NO and only the pap test will be ordered.</p> <p>b. If YES, HPV testing is desired, select one of two options:</p> <p>1. CO-TESTING (30-64 y/o)</p> <p>-If Co-testing is selected, the HPV test will be ordered and performed regardless of the pap test final diagnosis.</p> <p>Note: Co-testing is recommended for patients age 30-64.</p> <p>2. HPV REFLEX (see link below for criteria)</p> <p>-If reflex is selected the HPV test will only be performed in the following scenarios:</p> <p>a. The pap test final diagnosis is ASCUS and the patient is between ages 21-64.</p> <p>b. The pap test final diagnosis is LSIL and the patient is between ages 25-64</p>
<p>Thyroid FNA resulting in diagnosis of Bethesda category III AUS (Atypia of undetermined significance) or Bethesda category IV FN (Follicular neoplasm); when no concurrent thyroid malignancy is present.</p> <p>Bethesda System for Reporting Thyroid Cytopathology 3rd ed. 2023- updated 2/2025</p> <p style="text-align: right;">Per NCCN guidelines version 5.2024</p>	<p>Patients 21 years of age and older:</p> <ul style="list-style-type: none"> - Afirma Genomic Sequencing Classifier (GSC) and Malignancy Classifiers (BRAF, MTC, RET/PTC1 and RET/PTC3); to Veracyte (fresh sample in Afirma vial) <p>Patients under 21 years of age:</p> <ul style="list-style-type: none"> - ThyroSeq Genomic Classifier testing to CBL Path (fresh sample in ThyroSeq vial, FFPE cell block, or smeared slide)
Cytology– Optional	
Initial Test and Result	Optional Follow up Testing
Cervical Cytology with ASCUS, ASC-H OR LSIL	HPV-high risk
Cervical Cytology with ASCUS or AGUS	HPV
Cervical Cytology with NIL, ASCUS or AGUS	HPV

Flow Cytometry Reflex Testing

Flow Cytometry – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
Diagnostic sample of B-lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma with anti CD-19 therapy	Flow cytometry Blinatumomab tube (anti-CD19 therapy tubes)
Flow cytometry testing requiring CBC w diff for quantitation of flow cytometry results (i.e. SCID, ALPS, lymph subsets, CD20, etc)	<ol style="list-style-type: none"> 1. CBC w diff on all orders that do not already have a CBC w diff ordered on patient on the same date and specimen is less than 10 hours old. 2. And Flow cytometry is unable to get WBC and automated differential.
<p>Leukemia/Lymphoma/Myeloma and/or Non-Hodgkin lymphoma panels by flow cytometry: if indicated, reflex testing may be added to further characterize possible abnormal cell populations identified by the screening panel.</p> <p>These panels are reviewed continuously in multidisciplinary conferences and by the flow cytometry laboratory and hematopathologists.</p>	<p>The following add on panels may be employed after initial testing, as needed and appropriate, to further evaluate any possible abnormal population of cells.</p> <p>B lymphoblastic leukemia (B-ALL) panel T lymphoblastic leukemia (T-ALL) panel Chronic lymphocytic leukemia (CLL) panel Hairy cell leukemia (HCL) panel Extended B-cell tube panel Extended T-cell tube panel NK cell or LGL panel CD10 positive B-cell panel CD5 positive B-cell panel Acute myeloid leukemia (AML) panel Extended myeloid or monocytic panel Plasma cell panel Mast cell panel</p>
Flow Cytometry – Optional	
Initial Test and Result	Optional Follow up Testing
Fetal Cells by Flow Cytometry → If ordered STAT and received in lab outside of flow cytometry testing hours (after 3:30 Mon-Fri or after 10:00am Sat or Sun)	Fetal Hemoglobin by Kleihauer Betke performed in place of flow cytometry
<p>Leukemia or Non-Hodgkin Lymphoma Panel by Flow Cytometry →</p> <p>Cell population is diagnostic of circulating leukemia/lymphoma/myeloma, and patients under age of 80 with new diagnosis</p>	FISH testing

Hematology Reflex Testing

Hematology – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
CBC w/ diff - will reflex to CBC w/out diff "if" the WBC is less than or equal to 0.4. <small>Updated by Lab due to OEE March 2024</small>	CBC w/out differential
Cerebral Spinal Fluid (CSF) RBC Cell Count greater than or equal to 400 cells in tube 3 <small>Update Approved by MEC May 2022</small>	Additional count of tube 1
Cerebral Spinal Fluid (CSF) WBC Cell Count greater than 0, in tube 3	Manual differential
Mononucleosis Screen, Epstein Barr (EBV) IgM if Negative: If Mononucleosis Screen is Negative	Epstein Barr (EBV) VCA IgM Acute Antibody
Malaria Rapid Screen <ol style="list-style-type: none"> 1. If presumptive positive for malaria antigens 2. If presumptive negative for malaria antigens 	<ol style="list-style-type: none"> 1. Parasitemia Level; Malaria speciation confirmation by thin/thick smear microscopy evaluation 2. Negative result confirmed by thin/thick smear microscopy evaluation. If smear is positive, then reflex to Parasitemia Level
Pathologist Review If review of peripheral blood smear is ordered without required accompanying CBC with differential, and if the specimen is within 10 hours of collection.	Complete Blood Count (CBC) with Differential
Platelet Count less than 100,000/ μ L <small>Updated November 2021</small>	Immature platelet fraction (IPF)
Hematology – Optional	
Initial Test and Result	Optional Follow up Testing
CBC order →	Pathologist review
CBC specimens that fulfill criteria listed in Pathologist Review	
CBC w/ Diff →	Pathologist Review
CBC specimens that fulfill criteria listed in Pathologist Review	
CBC w/ Diff → WBC less than 3.0 or greater than 18.0 HGB less than 8.0 or greater than 18.0 MCV less than 75.0 or greater than 110.0 (updated 04/2021) Absolute neut count less than 1.50 or greater than 9.00 Absolute lymph count less than 0.39 or greater than 4.50 Absolute mono count greater than 1.50 Absolute eos count greater than 1.00 Absolute bas count greater than 0.20 Abnormal instrument flags suggesting abnormality	Manual WBC differential

Cell Ct only BFL order → Body fluid specimens that fulfill criteria listed in Pathologist Review	Pathologist review
--	--------------------

Hematopathology Reflex Testing

Hematopathology – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
Acute myeloid leukemia and myeloid neoplasms (includes MDS, MDS/MPN, and PMF—not CML, ET or P vera) : new diagnosis, patient of any age (Bone Marrow or Whole Blood)	Heme Molecular Sequence Analysis
All newly diagnosed patients with B-Cell Lymphomas with features concerning possible lymphoplasmacytic, unless otherwise specified by physician	MYD88 L265P and CXCR4 mutation testing on bone marrow aspirate Per NCCN guidelines 2/2026
Diffuse large B-cell lymphoma: new diagnosis, patient of any age	DLBCL panel by IHC (CD3, CD20, CD5, CD10, BCL-1, Ki-67, EBERish, BCL-2, BCL-6, MUM1, MYC, CD30, and CD45), FISH for high grade B-cell lymphoma (double hit BCL-2, BCL-6, MYC, with t(8;14) reflex)
New diagnosis of neoplastic hematopoietic population by leukemia/lymphoma/myeloma flow cytometry panel patient of any age	FISH testing as appropriate (use especially for new diagnosis of CLL in peripheral blood)
Bone marrow or blood EDTA samples (Philadelphia positive B-ALL and CML)	RNA extract and hold

Immunochemistry Reflex Testing

Immunochemistry – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
Celiac Disease Cascade Transglutaminase (TTG) IgA antibody and total IgA performed <div style="text-align: right;">Updated February 2025</div>	<ul style="list-style-type: none"> • Normal or high total IgA, weak positive TTG IgA (15 to 30U/mL): reflex Endomysial IgA • Low total IgA, negative TTG IgA (less than (<)15 U/mL): reflex TTG IgG, Gliadin IgG, and Gliadin IgA • Low total IgA, positive TTG IgA (greater than (>) 30 U/mL): reflex TTG IgG, Gliadin IgG, and Gliadin IgA • Low total IgA, weak positive TTG IgA (15-30 U/mL): reflex TTG IgG, Gliadin IgG, Gliadin IgA, and Endomysial IgA
Hemoglobin (Hgb) A2 result is greater than 10%	Capillars Hemoglobin Electrophoresis (to confirm Hgb E)
Hemoglobin Fractionation that identifies new Hemoglobin S	Sickle Cell Screen
Hemoglobin Fractionation	CBC on all orders for Hemoglobin Fractionation that do not already have a CBC ordered in the past 30 days.
Patient is less than 6 months of age and has suspected Hgb S by the Hgb fractionation test	Capillars Hemoglobin Electrophoresis
Patient is suspected of having Hgb C by the Hgb fractionation test	Capillars Hemoglobin Electrophoresis
Positive Cryoglobulin test <div style="text-align: right;">Updated May 2024</div>	Positive Cryoglobulins which have not had an identification in the past 12 months will have the Reflex Cryoglobulin Interpretation ordered.
Positive Lyme Disease Screen	Western Blot
Rapid Plasma Reagin (RPR) test for syphilis	SYPHILIS IgG SCREEN will be performed instead of the RPR.
Random Urine Protein Electrophoresis IFE if indicated	For order questions of Monitoring or General screen: reflex to urine immunofixation if abnormal protein electrophoresis. For order questions of AL amyloid: always reflex to urine immunofixation.
Serum Protein Electrophoresis IFE if indicated	For order questions of Monitoring or General screen: reflex to serum immunofixation if abnormal protein electrophoresis. For order questions of AL amyloid and neuropathy: always reflex to serum immunofixation.
24-hour Urine Protein Electrophoresis IFE if indicated	For order questions of Monitoring or General screen: reflex to urine immunofixation if abnormal protein electrophoresis. For order questions of AL amyloid: always reflex to urine immunofixation.

Immunochemistry – Optional	
Initial Test and Result	Optional Follow Up Testing
ANA screen order → If positive ANA	ANA Hep2 (IFA) if positive reflex to titer. If titer is equal or greater than 1:160 reflex to Anti-dsDNA, anti-Sm, anti-RNP, anti-SSA, anti-SSB, anti Scl70, anti-centromere and anti-Jo1
Peanut IgE reflex order → Peanut IgE => 0.35 kU/L <div style="text-align: right; font-size: small;">Updated February 2024</div>	Peanut component allergen panel (Peanut Ara h 1 IgE, Peanut Ara h 2 IgE, Peanut Ara h 3 IgE, Peanut Ara h 6 IgE, Peanut Ara h 8 IgE, and Peanut Ara h 9 IgE)
Egg IgE reflex order → Egg white IgE =>0.35 kU/L <div style="text-align: right; font-size: small;">Updated February 2024</div>	Egg component allergen Panel (Ovomucoid IgE and Ovalbumin IgE)
Milk IgE reflex order → Milk (cow) =>0.35 kU/L <div style="text-align: right; font-size: small;">Updated February 2024</div>	Milk component allergen Panel (Casein IgE, Alpha-Lactalbumin IgE, and Beta-lactoglobulin IgE)

Microbiology Reflex Testing

Microbiology – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
Anaerobic Culture	Aerobic culture on all orders that do not already have an aerobic culture ordered on the same specimen.
Blood Culture; if positive for growth of bacteria or yeast	<ul style="list-style-type: none"> • Organism identification will be performed if growth occurs any bottle. • Antimicrobial susceptibility testing will be performed depending on organism identification as per protocol.
Body Fluid culture greater than 1mL sample with only aerobic culture	Add anaerobic culture
Cryptococcus Antigen ordered on CSF	Fungal Culture order is added in addition to Cryptococcus Ag testing.
Clostridioides difficile by PCR	Clostridioides difficile PCR testing may only be ordered with approval from Infectious Disease. Other PCR orders are switched to C. difficile toxin EIA.
Culture from catheter tip or foreign bodies	Foreign body culture
Group A Streptococcus negative antigen test on pediatric patients	Add throat Culture
Positive culture for pathogen or organism with clinically significant concentration (bacteria or yeast)	Susceptibility and typing as necessary.
Positive Group B Strep, Penicillin allergy, PCR	Susceptibility testing.
Tissue Specimens ordered as a Body Fluid Culture	Cancel and Order as a Tissue Culture
Body Fluid Specimens ordered as a Tissue Culture	Cancel and Order as a Body Fluid Culture
Mycobacterium tuberculosis Complex PCR	AFB Culture with Smear

MEC Approved April 2025

Molecular Diagnostics Reflex Testing

Molecular Diagnostics – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
Myeloproliferative Neoplasms (MPN) <ol style="list-style-type: none"> 1. JAK2 V617F ordered without prior 12-month BCR-ABL 2. JAK2 V617F mutation negative with BCR-ABL negative within past 12 months. 	<ol style="list-style-type: none"> 1. BCR-ABL must be performed first - if negative then JAK2 V617F can be performed 2. 2.Then MPN Expanded Panel
Female urine specimens with Trichomonas Antigen testing ordered. <div style="text-align: right; font-size: small;">MEC Approved November 2022</div>	Cancel Trichomonas Antigen order and reorder as corresponding Trichomonas PCR order.
Male urine specimen collected in Abbott Multi Collect tube and ordered as Trichomonas Antigen <div style="text-align: right; font-size: small;">MEC Approved March 2024</div>	Cancel Trichomonas Antigen order and reorder as corresponding Trichomonas PCR order.

Referrals Reflex Testing

Referrals – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
Positive Gamma HydroxyButyrate (GHB)	GC/MS Confirmation (Mayo)
Blastomyces Antibody by EIA, Serum equivocal or Positive	Blastomyces Antibody by Immunodiffusion

Toxicology Reflex Testing

Toxicology – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
For obstetric inpatients (Mothers and their babies): Positive Amphetamine, Cannabinoids, Ethanol, Methadone, opiates, Oxycodone or cocaine on a Drug of Abuse screen. For OB 330 Residency: any positive analytes on a Drug of Abuse screen.	LC/MS Confirmation
Positive opiates on Comprehensive Drug Screens	LC/MS Confirmation
Lead Screen, Filter Paper order with whole blood sample. MEC Approved June 2023	Change order to Lead, Blood Level to match provided sample.
Lead, Blood Level order with filter paper sample collected. MEC Approved June 2023	Change order to Lead Screen, Filter Paper to match provided sample.

Transfusion Medicine/Blood Bank Reflex Testing

Transfusion Medicine – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
Antibody Screens	ABO/RH
Antibody Titer	ABO/Rh and Antibody Screen
All patients that are identified with hemoglobinopathy including: <ul style="list-style-type: none"> • hgSS • hgSC • beta thalassemia And have not been transfused in the last 3 months.	Serological C, E, and K antigen typing
NICU patients with a cord blood workup	Antibody Screen
Positive Antibody Screen, or a positive Direct Antiglobulin Test (DAT) on inpatients, outpatients, and surgical patients	Relevant studies as needed including antibody identification, antigen typing, direct antiglobulin test, elution and absorption. In addition, packed blood cells will be antigen typed and crossmatched.
Positive prenatal Profile Type & Antibody Screen	Antibody identification with titer if identified antibody is clinically significant
Women of childbearing age identified as RHD variants or "weak D phenotypes" via serological testing with no previous RHD genotyping on file.	Molecular RHD Genotyping
Type & Screen (T&S) on a patient with autologous or directed units	Crossmatch of the units
Type & Screen (T&S) on a pre-op patient with an antibody	Crossmatch of two antigen negative units
Patients with difficult antibody situation (e.g., red cell autoantibodies, multiple red cell antibodies or atypical serologic difficulties due to medication, rare antisera or broad serologic reactivity)	Testing for red cell genotyping (molecular testing) to further determine patient management, as deemed necessary by the Blood Bank physician/pathologist. <small>For more details, please see original MEC from 8/2021</small>
Known Sickle cell disease or thalassemia patient that is requiring transfusion and has not had a prior Red Cell Genotyping Panel <small>MEC Approved May 2024</small>	Red Cell Genotyping Panel. Lab Referrals Misc 848

Urinalysis Reflex Testing

Urinalysis – Mandatory	
Initial Test and Result	Confirmation Testing/Additional Workup
UA or UA culture if with inadequate volume for microscopic exam	Urine Dipstick (U dip)
Urinalysis – Optional	
Initial Test and Result	Optional Follow Up Testing
If urinalysis (UA) with two or more of the following abnormal findings, provided there are less than 10 squamous epithelial cells observed per high power field: -Greater than or equal to 10 WBC -Positive leukocyte esterase -Positive nitrite OR if specimen is -Grossly bloody	Urine Culture
If volume is inadequate for microscopic exam and Urine Dipstick (U dip) with one or more of the following abnormal findings: -Positive leukocyte esterase -Positive nitrite	Urine Culture